Table 2.
Study | n | Technique | Follow-up (month) | Flaccid penile shaft circumference (cm) | Flaccid penile length (cm) | Complication | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
Baseline | Endpoint | Gain | Baseline | Endpoint | Gain | Case (n) | Rate (%) | ||||
Nikoobakht et al.232011 | 23 | Extender | 3 | 8.8±1.2a | 10.5±1.2a | NR | NR | NR | NR | NR | NR |
Nowroozi et al.242015 | 54 | Extender | 6 | 8.6±1.0a | 10.3±1.4a | 1.7±0.8a | NR | NR | NR | NR | NR |
Gontero et al.252009 | 16 | Extender | 6 | NR | NR | 2.05±1.32a | NR | NR | 0.03d | NR | NR |
Aghamir et al.262006 | 30 | Vacuum pump | 8 | 6.9–9.4b | 7–9.7b | NR | NR | NR | NR | NR | NR |
Kang et al.272012 | 52 | Autologous fat injection | 6 | NR | NR | NR | 7.01±0.39a | 9.29±0.82a | NR | 1 | 1.92 |
Xu et al.202016 | 23 | Dermal fat graft | 6 | 6.27±0.53a | 8.54±0.99a | 2.27±0.54a | 8.25±0.60a | 9.92±0.89a | 1.67±0.46a | 23 | 100 |
Shaeer282014 | 40 | Flap | 18 | 5.8±1.3a | 8.5±1.4a | 31.8%a | 9.3±1.1a | 14.5±1.1a | 55.6%a | 40 | 100 |
Xu et al.292019 | 78 | Acellular dermal matrix | 3 | NR | NR | NR | NR | NR | 1.1 (0.5–2.1)c | 56 | 71.79 |
Alei et al.302012 | 69 | Acellular dermal matrix | 12 | 8.1 (5.4–10.7)c | 11.3 (8.2–13.2)c | NR | NR | NR | NR | 69 | 100 |
Jin et al.312011 | 69 | Collagen scaffold | 6 | NR | NR | NR | 8.18±0.83a | 12.19±1.27a | NR | 6 | 8.70 |
Protogerou et al.322010 | 40 | Ligament dissection | 12 | 9.5±2.2a | NR | 3.5±1.3a | NR | NR | NR | 1 | 2.5 |
Zhang et al.332016 | 17 | Dermal graft | 4 | 4.1±2.4a | 6.8±1.2a | 2.7±1.4a | 5.8±1.0a | 7.3±0.9a | 1.5±0.6a | 8 | 26.7 |
aMean±s.d.; brange; cmean (range); dmean. NR: not reported; s.d.: standard deviation